RxDoctor Payments Data

Himaxi Maisuria, MD

Cardiovascular Disease · Lexington, SCNPI 1902832058

Payments from drug & device makers

$2,518in general payments, 2019–2025

Across 103 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Terumo Medical Corporation$1K
  • Amgen$310
  • Novartis$304
  • AstraZeneca$140
  • Pfizer$133
  • Amarin Pharma, Inc.$78
  • plus $438 from 12 others

What the payments were for

  • Travel & lodging$1,00340%
  • Food & beverage$1,40356%
  • Education$1124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,518 in reported general payments places this provider in the 35th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$343,955
Medicare patients
1,118
Services billed
5,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$303,902
EntrestoSacubitril/Valsartan159$158,897
XareltoRivaroxaban101$85,017
Repatha SureclickEvolocumab30$39,611
Ranolazine ErRanolazine173$16,345
FarxigaDapagliflozin Propanediol12$13,916
JardianceEmpagliflozin14$13,914
MultaqDronedarone Hcl12$8,996
Metoprolol Succinate451$6,830
Janumet XrSitagliptin Phos/Metformin Hcl11$6,343
Rosuvastatin Calcium217$4,548
Losartan Potassium333$4,155
Potassium Chloride130$3,810
ClopidogrelClopidogrel Bisulfate277$3,221
Amiodarone Hcl111$2,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$303,902297 claims
NovartisEntresto$304$158,897159 claims
Johnson & JohnsonXarelto$50$85,017101 claims
AstraZenecaFarxiga$140$13,91612 claims
Boehringer IngelheimJardiance$64$13,91414 claims
MerckJanumet Xr$61$6,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →